Literature DB >> 19379464

Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer.

Masatsugu Ueda1, Michiko Yamamoto, Osamu Nunobiki, Eisaku Toji, Naomi Sato, Shinji Izuma, Yoshiaki Okamoto, Kiyo Torii, Sadamu Noda.   

Abstract

A functional T to G germline polymorphism in the promoter region of murine double-minute 2 homolog single nucleotide polymorphism 309 (MDM2-SNP309) has been reported to profoundly accelerate tumor formation, suggesting that it may also represent a powerful cancer predisposing allele. In this study, MDM2-SNP309 was examined in a total of 400 blood samples from 108 normal, 88 cervical, 119 endometrial and 85 ovarian cancer cases using two independent polymerase chain reaction assays for each allele. When the MDM2-SNP309 genotype was classified into two subgroups of TT+TG and GG, the GG genotype was associated with an increased risk for the development of endometrial cancer (odds ratio [OR]= 1.91, 95% confidence interval [CI] = 1.05 to 3.47) compared with the TT+TG genotype (P = 0.0353). The G allele also increased the risk of endometrial cancer (OR = 1.20, 95% CI = 0.83 to 1.74) compared with the T allele, but no statistical difference was found (P = 0.3333). The homozygous GG genotype was also associated with postmenopausal status and type I endometrial cancer (P = 0.0306 and 0.0326, respectively). There was no significant difference in the genotype or allele prevalence between control subjects and cervical or ovarian cancer patients. These results suggest that homozygous GG genotype of MDM2-SNP309 may be a risk factor for postmenopausal and type I endometrial cancer in a Japanese population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19379464     DOI: 10.1111/j.1749-0774.2009.00068.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  27 in total

Review 1.  Regulation of p53 function.

Authors:  D B Woods; K H Vousden
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

2.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein.

Authors:  J Chen; X Wu; J Lin; A J Levine
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

3.  p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status.

Authors:  K Niwa; T Murase; S Morishita; M Hashimoto; N Itoh; T Tamaya
Journal:  Cancer Detect Prev       Date:  1999

4.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.

Authors:  Gareth L Bond; Kim M Hirshfield; Tomas Kirchhoff; Gabriella Alexe; Elisabeth E Bond; Harlan Robins; Frank Bartel; Helge Taubert; Peter Wuerl; William Hait; Deborah Toppmeyer; Kenneth Offit; Arnold J Levine
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

5.  Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

Authors:  Christine S Walsh; Carl W Miller; Beth Y Karlan; H Phillip Koeffler
Journal:  Gynecol Oncol       Date:  2006-11-21       Impact factor: 5.482

Review 6.  Genetic association studies in digestive system malignancies.

Authors:  Christos Tsigris; Agape Chatzitheofylaktou; Constantinos Xiromeritis; Nikolaos Nikiteas; Athanasios Yannopoulos
Journal:  Anticancer Res       Date:  2007 Sep-Oct       Impact factor: 2.480

7.  Involvement of p53 gene mutations in human endometrial carcinomas.

Authors:  T Honda; H Kato; T Imamura; T Gima; J Nishida; M Sasaki; K Hoshi; A Sato; N Wake
Journal:  Int J Cancer       Date:  1993-04-01       Impact factor: 7.396

8.  Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.

Authors:  Frank Bartel; Juliane Jung; Anja Böhnke; Elise Gradhand; Katharina Zeng; Christoph Thomssen; Steffen Hauptmann
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

9.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

Review 10.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

View more
  19 in total

1.  MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis.

Authors:  Fang Fang; Xiao-Jia Yu; Lu Yu; Lei Yao
Journal:  Med Oncol       Date:  2010-05-26       Impact factor: 3.064

Review 2.  MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.

Authors:  Yan Li; Hongjin Zhao; Li Sun; Linjuan Huang; Qifeng Yang; Beihua Kong
Journal:  Hum Cell       Date:  2011-03-04       Impact factor: 4.174

3.  Common variant on MDM2 contributes to endometrial cancer susceptibility: evidence based on 7 studies.

Authors:  Yan Zhao; Xiaoer Yang; Xiaojiao Hao; Xiaolin Pan; Bo Zhao; Jingwen Ma; Jian Fang; Minghong Zhao
Journal:  Tumour Biol       Date:  2014-05-03

4.  Germline mutations and polymorphisms in the origins of cancers in women.

Authors:  Kim M Hirshfield; Timothy R Rebbeck; Arnold J Levine
Journal:  J Oncol       Date:  2010-01-10       Impact factor: 4.375

5.  MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis.

Authors:  Li-Hong Wang; Xu Wang; Wen-Ting Xu; Ya-Li Hu
Journal:  Tumour Biol       Date:  2013-11-30

Review 6.  Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes.

Authors:  Shing Cheng Tan; Ravindran Ankathil
Journal:  Tumour Biol       Date:  2015-08-05

7.  MDM2 SNP309 variation increases cervical cancer risk among Asians.

Authors:  Xianlu Zhuo; Jie Ren; Dairong Li; Yongzhong Wu; Qi Zhou
Journal:  Tumour Biol       Date:  2014-02-15

8.  MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.

Authors:  Yan Wan; Wei Wu; Zhihua Yin; Peng Guan; Baosen Zhou
Journal:  BMC Cancer       Date:  2011-05-29       Impact factor: 4.430

9.  Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.

Authors:  Merete Bjørnslett; Stian Knappskog; Per Eystein Lønning; Anne Dørum
Journal:  BMC Cancer       Date:  2012-10-05       Impact factor: 4.430

10.  The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.

Authors:  Ying-Yu Ma; Tian-Pei Guan; Hai-Bo Yao; Sheng Yu; Le-Gao Chen; Ying-Jie Xia; Xu-Jun He; Hui-Ju Wang; Xiao-Ting Jiang; Hou-Quan Tao
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.